Alzheimer's Destruction Ways - Decoy Receptors

We can say that the struggle with Alzheimer is a big step nowadays. We learn Alzheimer's treatment methods in the light of the theories and the evidence. One of them was shared in the past days. With the Decoy Receptors method you can minimize or even eliminate Alzheimer's effect. Now, what is Decoy Receptors and how it works, let's examine it together.

One day, it might be possible to harness the immune system and coerce it into tackling Alzheimer's disease. A recent study brings us one step closer to making this a reality.

Alzheimer's disease is a neurodegenerative condition that affects around 5.7 million individuals in the United States.

Around 1 in 10 people over the age of 65 have Alzheimer's. Despite its worrying prevalence, there is still no cure and no way to slow its progression.

The exact mechanisms behind Alzheimer's are not fully understood, but a toxic buildup of a protein called beta-amyloid is known to be important. As levels of amyloid plaques increase, nerve cells begin to die off.

Over the years, it has become increasingly clear that the immune system plays a role in this disruptive condition. However, it is a complicated and double-edged relationship.

For instance, the immune system has the potential to slow Alzheimer's progression by clearing up toxic protein; on the other hand, immune cells can react to amyloid plaques and trigger an inflammatory response that, in the long run, causes more damage to brain tissue.

The importance of microglia

One type of immune cell that seems pivotal is microglia, which are a type of macrophage that forms the brain's first line of defense. These cells are responsible for clearing the brain of debris, toxins, and pathogens.

In Alzheimer's disease, however, microglia do not fulfill their duty. Dysfunction of these cells may, at least in part, be responsible for the buildup of amyloid plaques in the brain.

The latest research into Alzheimer's and the immune response comes from the University of Florida in Gainesville. Led by Paramita Chakrabarty, Ph.D., and Dr. Todd E. Golde, the scientists were particularly interested in a family of proteins called toll-like receptors (TLRs).

Source: https://www.medicalnewstoday.com/articles/322890.php